GERN - long - Catalyst play

10 févr.

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's leading drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses global rights to this drug. the company operates as a single segment, the development of therapeutic products for oncology.

This is not a financial advice!

Recent block buys

Upcoming catalyst on 14th of March

Keep an eye on 2.35 level - needs to get broken for a further upmove.

SL under 1.9

TP approx. 3.0

Most info on the chart.

Trade carefully!

13 févr.

Note

moneyyyy

20 févr.

Trade fermée: ordre d’arrêt atteint